机构：[1]Department of Traditional Chinese Medicine, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan 430060, P. R, China.[2]Department of Integrated Traditional Chinese and Western Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming 650019, Yunnan, China.[3]Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China.
This project was supported by Wuhan Medical Research
Project (Youth Project) [WZ19Q02] and Innovative Seed
Funds of the Medical College of Wuhan University
[TFZZ2018027].
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类|4 区医学
小类|4 区生化研究方法4 区应用化学4 区药学
最新[2025]版：
大类|4 区医学
小类|4 区生化研究方法4 区应用化学4 区药学
第一作者：
第一作者机构：[1]Department of Traditional Chinese Medicine, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan 430060, P. R, China.
共同第一作者：
通讯作者：
通讯机构：[*1]Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China
推荐引用方式(GB/T 7714)：
Xie Ping,Jin Xiaowei,Li Chan,et al.Huazhi Rougan Granule Alleviates Liver and Intestinal Damage in Non-Alcoholic Fatty Liver Disease by Regulating miR-122 Expression and TLR4/MyD88/NF-κB Pathway Activation[J].Combinatorial Chemistry & High Throughput Screening.2024,doi:10.2174/0113862073290372240603090844.
APA：
Xie Ping,Jin Xiaowei,Li Chan,Lv Kun&Deng Ming.(2024).Huazhi Rougan Granule Alleviates Liver and Intestinal Damage in Non-Alcoholic Fatty Liver Disease by Regulating miR-122 Expression and TLR4/MyD88/NF-κB Pathway Activation.Combinatorial Chemistry & High Throughput Screening,,
MLA：
Xie Ping,et al."Huazhi Rougan Granule Alleviates Liver and Intestinal Damage in Non-Alcoholic Fatty Liver Disease by Regulating miR-122 Expression and TLR4/MyD88/NF-κB Pathway Activation".Combinatorial Chemistry & High Throughput Screening .(2024)
